Cerus (NASDAQ:CERS) CFO Kevin Dennis Green Sells 27,796 Shares

Cerus Corporation (NASDAQ:CERS) CFO Kevin Dennis Green sold 27,796 shares of the business’s stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $2.01, for a total transaction of $55,869.96. Following the transaction, the chief financial officer owned 1,168,095 shares in the company, valued at approximately $2,347,870.95. The trade was a 2.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Cerus Price Performance

Shares of CERS opened at $1.93 on Tuesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.17 and a current ratio of 1.73. The company has a 50-day simple moving average of $2.31 and a 200-day simple moving average of $1.86. Cerus Corporation has a 52 week low of $1.12 and a 52 week high of $2.96. The firm has a market capitalization of $370.89 million, a P/E ratio of -24.13 and a beta of 1.51.

Cerus (NASDAQ:CERS) last released its earnings results on Monday, March 2nd. The biotechnology company reported ($0.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.01). Cerus had a negative return on equity of 26.09% and a negative net margin of 7.58%.The business had revenue of $64.58 million for the quarter, compared to the consensus estimate of $59.31 million. On average, equities research analysts expect that Cerus Corporation will post -0.08 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CERS. Vanguard Group Inc. boosted its holdings in Cerus by 0.6% during the third quarter. Vanguard Group Inc. now owns 10,783,986 shares of the biotechnology company’s stock valued at $17,147,000 after purchasing an additional 62,663 shares in the last quarter. Wasatch Advisors LP lifted its position in shares of Cerus by 2.6% during the 2nd quarter. Wasatch Advisors LP now owns 8,533,758 shares of the biotechnology company’s stock worth $12,033,000 after buying an additional 213,917 shares during the period. Millennium Management LLC boosted its stake in Cerus by 17.6% in the 3rd quarter. Millennium Management LLC now owns 3,470,062 shares of the biotechnology company’s stock valued at $5,517,000 after buying an additional 519,301 shares in the last quarter. Acadian Asset Management LLC boosted its stake in Cerus by 38.6% in the 2nd quarter. Acadian Asset Management LLC now owns 2,632,304 shares of the biotechnology company’s stock valued at $3,710,000 after buying an additional 733,683 shares in the last quarter. Finally, Ieq Capital LLC grew its position in Cerus by 1.1% in the fourth quarter. Ieq Capital LLC now owns 2,423,741 shares of the biotechnology company’s stock valued at $4,993,000 after acquiring an additional 25,771 shares during the period. Institutional investors own 78.37% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on CERS shares. Wall Street Zen cut Cerus from a “buy” rating to a “hold” rating in a research report on Saturday. TD Cowen reaffirmed a “buy” rating on shares of Cerus in a research report on Monday, January 12th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Cerus currently has an average rating of “Hold”.

Key Headlines Impacting Cerus

Here are the key news stories impacting Cerus this week:

• Neutral Sentiment: Short-interest data flagged an apparent increase for the March 9 reporting period but shows 0 shares and reports a days-to-cover of 0.0 — the print looks incorrect or incomplete and should be treated as unreliable until exchanges update filings.
• Neutral Sentiment: Analysts overview: The Globe and Mail ran a piece discussing analysts’ views on Cerus alongside peers (Fennec). That coverage provides context but does not appear to contain new company-specific catalysts. Analysts Offer Insights on Healthcare Companies: Cerus (CERS) and Fennec Pharmaceuticals (FENC)
• Negative Sentiment: Insider selling: several insiders disclosed sales between Mar. 5–9 that reduce insider ownership by low-single-digit to mid-single-digit percentages. Notable filings: CEO William Mariner Greenman sold 78,187 shares (~$157k). COO Vivek Jayaraman sold 34,094 shares (~$68.5k). CFO Kevin D. Green sold 27,796 shares (~$55.9k). Director Richard J. Benjamin reported multiple sales (61,233; 40,426; 24,235 shares) at ~$2.06–$1.88 across Mar. 5–9. Insider Chrystal Jensen sold 30,845 shares (~$62k). Collectively, these are meaningful in signaling added supply and may weigh on sentiment even if sales were for personal/liquidity reasons. CEO filing: http://www.sec.gov/Archives/edgar/data/1020214/000137725826000004/xslF345X05/ownership.xml COO filing: http://www.sec.gov/Archives/edgar/data/1020214/000160545626000004/xslF345X05/ownership.xml Chrystal Jensen filing: http://www.sec.gov/Archives/edgar/data/1020214/000156425226000004/xslF345X05/ownership.xml Richard Benjamin filings: http://www.sec.gov/Archives/edgar/data/1020214/000129632226000004/xslF345X05/ownership.xml CFO filing: http://www.sec.gov/Archives/edgar/data/1020214/000145935126000005/xslF345X05/ownership.xml

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.